KR102755145B1 - 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 - Google Patents

장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 Download PDF

Info

Publication number
KR102755145B1
KR102755145B1 KR1020237040260A KR20237040260A KR102755145B1 KR 102755145 B1 KR102755145 B1 KR 102755145B1 KR 1020237040260 A KR1020237040260 A KR 1020237040260A KR 20237040260 A KR20237040260 A KR 20237040260A KR 102755145 B1 KR102755145 B1 KR 102755145B1
Authority
KR
South Korea
Prior art keywords
pp3m
dose
pharmaceutical composition
paliperidone palmitate
pp1m
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237040260A
Other languages
English (en)
Korean (ko)
Other versions
KR20230162162A (ko
Inventor
스리하리 고팔
파울린 게라르다 마리아 라벤스티즌
알베르토 루스수
마헤시 나레인 삼타니
Original Assignee
잔센파마슈티카엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57072843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102755145(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 잔센파마슈티카엔.브이. filed Critical 잔센파마슈티카엔.브이.
Priority to KR1020257000920A priority Critical patent/KR20250013293A/ko
Publication of KR20230162162A publication Critical patent/KR20230162162A/ko
Application granted granted Critical
Publication of KR102755145B1 publication Critical patent/KR102755145B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237040260A 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획 Active KR102755145B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257000920A KR20250013293A (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562144054P 2015-04-07 2015-04-07
US62/144,054 2015-04-07
US201562162596P 2015-05-15 2015-05-15
US62/162,596 2015-05-15
KR1020177031672A KR102606678B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
PCT/US2016/024841 WO2016164218A1 (en) 2015-04-07 2016-03-30 Dosing regimen for missed doses for long-acting injectable paliperidone esters

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177031672A Division KR102606678B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257000920A Division KR20250013293A (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Publications (2)

Publication Number Publication Date
KR20230162162A KR20230162162A (ko) 2023-11-28
KR102755145B1 true KR102755145B1 (ko) 2025-01-14

Family

ID=57072843

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237040260A Active KR102755145B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR1020177031672A Active KR102606678B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR1020257000920A Pending KR20250013293A (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177031672A Active KR102606678B1 (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
KR1020257000920A Pending KR20250013293A (ko) 2015-04-07 2016-03-30 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획

Country Status (27)

Country Link
US (1) US10143693B2 (enExample)
EP (3) EP3280416B1 (enExample)
JP (3) JP6728221B2 (enExample)
KR (3) KR102755145B1 (enExample)
AU (4) AU2016244801B2 (enExample)
BR (1) BR112017021383A2 (enExample)
CA (2) CA3088401A1 (enExample)
CY (1) CY1123203T1 (enExample)
DK (2) DK3744326T3 (enExample)
EA (1) EA037185B1 (enExample)
ES (2) ES2802299T3 (enExample)
FI (1) FI3744326T3 (enExample)
HR (2) HRP20201027T1 (enExample)
HU (2) HUE065435T2 (enExample)
IL (3) IL254669B2 (enExample)
LT (2) LT3744326T (enExample)
MA (1) MA41917B1 (enExample)
MD (2) MD3280416T2 (enExample)
NZ (1) NZ735952A (enExample)
PL (2) PL3280416T3 (enExample)
PT (2) PT3744326T (enExample)
RS (2) RS65024B1 (enExample)
SI (2) SI3280416T1 (enExample)
SM (2) SMT202000351T1 (enExample)
TW (1) TWI694825B (enExample)
UA (1) UA118732C2 (enExample)
WO (1) WO2016164218A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3744326T3 (da) 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere
EP3700531B1 (en) 2017-10-27 2025-06-25 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
EP4025188B1 (en) * 2020-11-30 2024-01-10 Janssen Pharmaceutica NV Dosing regimens associated with extended release paliperidone injectable formulations
PL4005555T3 (pl) 2020-11-30 2024-09-02 Janssen Pharmaceutica Nv Sposoby zapewniania ponownego zawieszenia preparatów palmitynianu paliperydonu
SI4025187T1 (sl) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi odmerjanja, povezani s formulacijami paliperidona za injiciranje s podaljšanim sproščanjem
CN116528836A (zh) 2020-11-30 2023-08-01 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.
CA3230291A1 (en) * 2021-08-30 2023-03-09 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
KR102869809B1 (ko) 2023-11-21 2025-10-13 주식회사 엘지에너지솔루션 양극 및 이를 포함하는 전고체 전지
CN121914111A (zh) * 2026-03-27 2026-04-24 济南大学 一种小粒度棕榈酸帕利哌酮的结晶工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
CN101163702B (zh) 2005-04-25 2011-09-07 詹森药业有限公司 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法
CA2655335C (en) * 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
US8758780B2 (en) * 2009-10-06 2014-06-24 Ascendis Pharma As Subcutaneous paliperidone composition
AU2010313290A1 (en) * 2009-10-30 2012-05-17 Janssen Pharmaceutica Nv Dosing regimen associated with long-acting injectable paliperidone esters
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
DK3744326T3 (da) 2015-04-07 2024-02-05 Janssen Pharmaceutica Nv Doseringsregime for glemte doser til langtidsvirkende injicerbare paliperidonestere

Also Published As

Publication number Publication date
AU2022221405A1 (en) 2022-09-15
KR20230162162A (ko) 2023-11-28
NZ735952A (en) 2022-02-25
EA201792209A1 (ru) 2018-02-28
MA41917B1 (fr) 2020-07-29
JP7228503B2 (ja) 2023-02-24
AU2016244801B2 (en) 2020-06-25
PL3744326T3 (pl) 2024-03-25
MD3744326T2 (ro) 2024-05-31
AU2020239611B2 (en) 2022-07-21
EP3744326B1 (en) 2023-12-06
NZ758246A (en) 2024-05-31
TWI694825B (zh) 2020-06-01
MD3280416T2 (ro) 2020-10-31
HUE049485T2 (hu) 2020-09-28
IL254669B2 (en) 2024-05-01
EA037185B1 (ru) 2021-02-17
WO2016164218A1 (en) 2016-10-13
IL324059A (en) 2025-12-01
IL309340A (en) 2024-02-01
IL254669B1 (en) 2024-01-01
RS65024B1 (sr) 2024-01-31
HRP20201027T1 (hr) 2020-12-11
JP2018510894A (ja) 2018-04-19
JP2021130680A (ja) 2021-09-09
CY1123203T1 (el) 2021-10-29
ES2802299T3 (es) 2021-01-18
US20170281629A1 (en) 2017-10-05
AU2022221405B2 (en) 2024-08-01
TW201642863A (zh) 2016-12-16
EP3744326A1 (en) 2020-12-02
SI3744326T1 (sl) 2024-02-29
EP3280416A4 (en) 2019-01-23
AU2020239611A1 (en) 2020-10-15
UA118732C2 (uk) 2019-02-25
AU2016244801A1 (en) 2017-10-05
KR20250013293A (ko) 2025-01-31
JP7422277B2 (ja) 2024-01-26
CA3088401A1 (en) 2016-10-07
CA2925908C (en) 2020-09-01
BR112017021383A2 (pt) 2018-07-03
LT3280416T (lt) 2020-06-25
SI3280416T1 (sl) 2020-07-31
EP3280416B1 (en) 2020-04-22
ES2967585T3 (es) 2024-05-03
EP3280416A1 (en) 2018-02-14
HRP20240022T1 (hr) 2024-03-29
DK3744326T3 (da) 2024-02-05
IL309340B1 (en) 2026-01-01
JP6728221B2 (ja) 2020-07-22
DK3280416T3 (da) 2020-05-11
KR20170134583A (ko) 2017-12-06
PT3280416T (pt) 2020-06-30
EP4349323A2 (en) 2024-04-10
CA2925908A1 (en) 2016-10-07
IL254669A0 (en) 2017-11-30
RS60510B1 (sr) 2020-08-31
AU2024227790A1 (en) 2024-11-21
PL3280416T3 (pl) 2020-12-14
SMT202300478T1 (it) 2024-01-10
SMT202000351T1 (it) 2020-09-10
EP4349323A3 (en) 2024-06-12
FI3744326T3 (fi) 2024-02-02
JP2020090498A (ja) 2020-06-11
KR102606678B1 (ko) 2023-11-24
HK1249047A1 (en) 2018-10-26
LT3744326T (lt) 2023-12-27
HUE065435T2 (hu) 2024-05-28
US10143693B2 (en) 2018-12-04
PT3744326T (pt) 2024-01-15

Similar Documents

Publication Publication Date Title
AU2022221405B2 (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
KR102794804B1 (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR20230116837A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR20230116836A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
HK40110149A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK40044495B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters
HK1249047B (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231122

Application number text: 1020177031672

Filing date: 20171031

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240314

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241009

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250110

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250110

End annual number: 3

Start annual number: 1

PG1601 Publication of registration